0001127602-19-008415.txt : 20190226 0001127602-19-008415.hdr.sgml : 20190226 20190226170919 ACCESSION NUMBER: 0001127602-19-008415 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190222 FILED AS OF DATE: 20190226 DATE AS OF CHANGE: 20190226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALEXANDER SUSAN H CENTRAL INDEX KEY: 0001263839 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 19634417 MAIL ADDRESS: STREET 1: C/O BIOGEN IDEC INC. STREET 2: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-02-22 0000875045 BIOGEN INC. BIIB 0001263839 ALEXANDER SUSAN H BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142 1 EVP Chief Legal Officer & Sec. Common Stock 2019-02-22 4 M 0 1663 0 A 29690 D Common Stock 2019-02-22 4 M 0 6395 48.52 A 36085 D Common Stock 2019-02-22 4 F 0 3370 325.33 D 32715 D Common Stock 2019-02-22 4 F 0 739 325.33 D 31976 D Restricted Stock Unit 0 2019-02-22 4 M 0 1663 0 D 2019-02-22 Common Stock 1663 819 D Restricted Stock Unit 0 2019-02-22 4 J 0 819 0 D 2019-02-22 Common Stock 819 0 D Stock Option (Right to Buy) 49.65 2019-02-22 4 M 0 6395 D 2019-02-24 Common Stock 6395 0 D The stock option was automatically exercised on a net share settlement basis immediately before its expiration, in accordance with its terms. The Company delivered to the reporting person the number of shares underlying the stock option less the number of shares having a Fair Market Value on the date of such exercise equal to (i) the aggregate exercise price for the stock option and (ii) the amount necessary to satisfy any federal, state and local withholding taxes related to such exercise. This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. The stock options become exercisable in four (4) equal annual installments commencing one year after the grant date of 02/24/09. /s/ Suzanne Murray, Attorney in Fact for Susan Alexander 2019-02-26